StockData
Sangamo Therapeutics, Inc logo

Sangamo Therapeutics, Inc (SGMOQ) stock

SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026Score 4/30
$0.10−0.01 (-8.17%)

Close on Oct 19, 2026Market cap $39.43MP/E –Yield –

Sangamo Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Sangamo Therapeutics's revenue for the twelve months ending Mar 31, 2026 was $34.56M, down 45.8% year over year. For fiscal 2025 it was $39.55M, down 31.6% from the year before. Over ten years it grew 0.0% a year on average. The highest annual figure on record is $176.23M in fiscal 2023.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$39.55M-31.6%
FY2024Dec 31, 2024$57.80M-67.2%
FY2023Dec 31, 2023$176.23M+58.3%
FY2022Dec 31, 2022$111.30M+0.5%
FY2021Dec 31, 2021$110.70M-6.3%
FY2020Dec 31, 2020$118.19M+15.4%
FY2019Dec 31, 2019$102.43M+21.3%
FY2018Dec 31, 2018$84.45M+131.0%
FY2017Dec 31, 2017$36.57M+88.6%
FY2016Dec 31, 2016$19.39M-51.0%
FY2015Dec 31, 2015$39.54M-13.8%
FY2014Dec 31, 2014$45.87M+90.1%
FY2013Dec 31, 2013$24.13M+11.4%
FY2012Dec 31, 2012$21.66M+109.9%
FY2011Dec 31, 2011$10.32M-50.4%
FY2010Dec 31, 2010$20.81M-6.2%
FY2009Dec 31, 2009$22.19M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2026Mar 31, 2026$1.44M-77.6%
Q4 FY2025Dec 31, 2025$14.23M+88.4%
Q3 FY2025Sep 30, 2025$581.00K-98.8%
Q2 FY2025Jun 30, 2025$18.31M+5042.1%
Q1 FY2025Mar 31, 2025$6.44M+1238.3%
Q4 FY2024Dec 31, 2024$7.55M+269.8%
Q3 FY2024Sep 30, 2024$49.41M+425.8%
Q2 FY2024Jun 30, 2024$356.00K-94.8%
Q1 FY2024Mar 31, 2024$481.00K-99.7%
Q4 FY2023Dec 31, 2023$2.04M-92.5%
Q3 FY2023Sep 30, 2023$9.40M-64.5%
Q2 FY2023Jun 30, 2023$6.84M-76.7%
Q1 FY2023Mar 31, 2023$157.96M+459.5%
Q4 FY2022Dec 31, 2022$27.23M-2.7%
Q3 FY2022Sep 30, 2022$26.46M-7.4%
Q2 FY2022Jun 30, 2022$29.38M+5.4%
Q1 FY2022Mar 31, 2022$28.23M+7.4%
Q4 FY2021Dec 31, 2021$27.99M+8.5%
Q3 FY2021Sep 30, 2021$28.56M-50.6%
Q2 FY2021Jun 30, 2021$27.87M+29.3%
Q1 FY2021Mar 31, 2021$26.28M+101.0%
Q4 FY2020Dec 31, 2020$25.80M-53.0%
Q3 FY2020Sep 30, 2020$57.76M+163.1%
Q2 FY2020Jun 30, 2020$21.55M+22.8%
Q1 FY2020Mar 31, 2020$13.08M+62.0%
Q4 FY2019Dec 31, 2019$54.85M+104.4%
Q3 FY2019Sep 30, 2019$21.96M-6.8%
Q2 FY2019Jun 30, 2019$17.55M-18.1%
Q1 FY2019Mar 31, 2019$8.07M-36.1%
Q4 FY2018Dec 31, 2018$26.84M+105.2%
Q3 FY2018Sep 30, 2018$23.56M+99.5%
Q2 FY2018Jun 30, 2018$21.42M+159.5%
Q1 FY2018Mar 31, 2018$12.64M+269.0%
Q4 FY2017Dec 31, 2017$13.08M+46.6%
Q3 FY2017Sep 30, 2017$11.81M+318.4%
Q2 FY2017Jun 30, 2017$8.25M+122.9%
Q1 FY2017Mar 31, 2017$3.43M–
Q4 FY2016Dec 31, 2016$8.92M–
Q3 FY2016Sep 30, 2016$2.82M–
Q2 FY2016Jun 30, 2016$3.70M–

More Sangamo Therapeutics figures

See a number that looks wrong?